Dr. Mina Tadrous

Scientist, Women’s College Hospital and Investigator

Ontario Drug Policy Research Network

Mina is a scientist at the Women’s College Hospital Institute for Health System Solutions and Virtual Care (WIHV). He is a pharmacoepidemiologist and pharmacist and also an assistant professor at the Leslie Dan Faculty of Pharmacy at the University of Toronto and investigator with the Ontario Drug Policy Research Network (ODPRN). He completed a PhD in pharmacoepidemiology at the University of Toronto and previously completed a Masters in Health Outcomes and Policy Research at the University of Tennessee, and a Doctor of Pharmacy at Albany College of Pharmacy. He also completed a pharmacy residency in Drug Information and Health Outcomes at the University of Tennessee and St. Jude Children’s Research Hospital.

Mina’s research interests lie in developing real-world evidence to inform provincial and national drug policy and the post-marketing surveillance of medications. He has a keen interest in leveraging big data to answer important health care questions. Specifically, he is driven to ensure the appropriate and safe use of medications and the sustainability of public drug programs.

All Sessions by Dr. Mina Tadrous

Printer Friendly See Full Agenda

Day 1: Oct 6, 2020

2:10 pm

2:10 pm

Panel Discussion

Gain Insights into the Impact of the Increasing Use of Biosimilars for Patients and the Marketplace

Many consider that increasing the use of biosimilars is key to putting healthcare budgets on a more financially sustainable path.  Understand the implications and opportunities for your business of recent policy decisions to foster a greater market share for biosimilars.  Develop an action plan to:

  • Prepare and support patients in the event they need to switch to a biosimilar
  • Analyse the impact on your biosimilar strategy of international collaboration to increase biosimilar market share
  • Adapt your Canadian market access strategies with medical and public policy guidance

Inform your strategy for biosimilars with key public policy insights

Day 2: Oct 7, 2020

Day 3: Oct 8, 2020